# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0220 |
| Population Package | PP-0220 |
| Title | Surveillance After Gastric Cancer Treatment |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Source-First Status | PASS |
| Locked Decision Status | PASS |

---

# QA Scope

This QA report evaluates the four-artifact PP-0220 Gold package against:

1. The approved and locked PP-0220 Decision Batch.
2. CORE_WORKING_RULES v1.7.
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.
4. DOCUMENT_ARCHITECTURE v2.0.
5. Approved Gold Discussion format/depth reference.
6. Supplied clinical Source Materials, with NCCN Gastric Cancer v2.2026 as the primary disease-specific source.

QA is substantive and includes content, clinical, educational and governance layers.

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | The package answers how patients are followed after gastric-cancer treatment. |
| Scope respected | PASS | Longitudinal surveillance is central; recurrence diagnosis, treatment and survivorship remain separated. |
| Scope completeness | PASS | Clinical visits, H&P, labs, EGD, imaging, anatomy-dependent differences, nutritional monitoring, timing, evidence limitations and transitions are covered. |
| Stage/treatment dependence | PASS | GAST-7 pathway differences are preserved. |
| Endoscopic-resection pathway | PASS | ER-specific surveillance is explicitly represented. |
| Surgical-resection pathway | PASS | Surgical follow-up and clinically indicated EGD are distinguished. |
| Total-gastrectomy pathway | PASS | Routine endoscopy exception and nutritional monitoring are represented. |
| Partial/subtotal gastrectomy | PASS | EGD and nutritional interfaces are preserved. |
| Imaging surveillance | PASS | Structured CT pathway and clinically indicated imaging pathways are distinguished. |
| Nutritional surveillance | PASS | Nutritional deficiency monitoring is treated as part of post-gastrectomy follow-up. |
| Five-year framework | PASS | Five-year routine surveillance framework and possible additional follow-up are distinguished. |
| Late recurrence context | PASS | Late actionable relapse is explicitly preserved. |
| Evidence uncertainty | PASS | NCCN's uncertainty and evidence limitations are not hidden. |
| Recurrence interface | PASS | Surveillance is separated from recurrence detection. |
| Survivorship interface | PASS | Surveillance is separated from survivorship. |
| Common misconceptions | PASS | Key patient-facing misconceptions are addressed. |
| Patient questions | PASS | Questions cover schedule, tests, anatomy, recurrence and long-term care. |
| Knowledge Graph | PASS | Prerequisite, related and downstream relationships are defined. |
| Cross-artifact scope consistency | PASS | CKO, KP and EP use the same locked scope. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Primary disease-specific source identified | PASS | NCCN Gastric Cancer v2.2026 is the dominant source. |
| GAST-7 identified | PASS | Follow-up/Surveillance is explicitly represented. |
| GAST-H identified | PASS | Principles of Surveillance are explicitly represented. |
| GAST-I interface identified | PASS | Survivorship boundary is explicit. |
| GAST-8 interface identified | PASS | Recurrence boundary is explicit. |
| H&P interval represented correctly | PASS | 3–6 months for 1–2 years, then 6–12 months for 3–5 years. |
| CBC/chemistry wording | PASS | “As clinically indicated” is preserved. |
| ER EGD schedule | PASS | Pathway-specific schedules are distinguished. |
| Surgical EGD | PASS | Described as clinically indicated where specified. |
| Total gastrectomy EGD exception | PASS | Routine endoscopy is not represented as universal after total gastrectomy. |
| CT surveillance | PASS | Structured CT interval is restricted to the appropriate pStage II/III or ypStage I–III pathway. |
| CT alternatives | PASS | PET/CT or MRI are described only as clinically indicated alternatives where CT cannot be performed. |
| Nutritional deficiency monitoring | PASS | Post-gastrectomy nutritional monitoring is represented. |
| Nutrient examples | PASS | B12, iron, zinc, calcium and vitamin D are represented. |
| Recurrence timing | PASS | 70–80% within two years and ~90% by five years are attributed to NCCN's evidence summary and not presented as individual risk. |
| Late recurrence | PASS | Potentially actionable relapse >5 years is preserved. |
| Evidence uncertainty | PASS | Sparse prospective data and retrospective/expert-consensus basis are explicit. |
| No universal schedule claim | PASS | The package avoids a one-size-fits-all schedule. |
| No universal tumor-marker schedule | PASS | Not invented. |
| No individualized surveillance prescription | PASS | Patient-facing content remains general and governed. |
| No individualized prognosis | PASS | Population-level recurrence timing is not converted to patient-specific risk. |
| No unsafe treatment advice | PASS | No treatment initiation/change/cessation instructions. |
| No recurrence diagnosis | PASS | Abnormal findings are routed to further evaluation. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Patient-facing educational intent | PASS | The package explains surveillance rather than merely listing tests. |
| Plain language | PASS | Technical terms are explained when introduced. |
| Logical progression | PASS | Definition → purpose → components → treatment-specific differences → timing → limitations → recurrence/survivorship interfaces. |
| Independent knowledge blocks | PASS | CKO uses distinct clinical knowledge blocks. |
| Patient explanation | PASS | A direct patient-facing explanation is included. |
| Common misconceptions | PASS | Ten major misconceptions are addressed. |
| Patient questions | PASS | Questions are practical and aligned with the package scope. |
| Uncertainty communication | PASS | Surveillance evidence limitations are explained without undermining the guideline framework. |
| No false reassurance | PASS | Normal tests are not described as guarantees. |
| No alarmism | PASS | Recurrence is discussed without implying that recurrence is inevitable. |
| Treatment-context dependence | PASS | The patient is told why schedules differ. |
| Long-term-care transition | PASS | End of routine surveillance is not equated with end of healthcare. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| Source-First execution | PASS | PP-specific clinical materials were searched before production. |
| Requested PP identity verified | PASS | PP-0220 is explicitly present in the authoritative PP Registry. |
| Adjacent PP check | PASS | PP-0219, PP-0221, PP-0222, PP-0229 and PP-0230 were incorporated into boundary logic. |
| Gold Discussion reference used | PASS | PP Discussion depth and format example was reviewed. |
| Gold specification used | PASS | Four-artifact structure and depth requirements were followed. |
| Four required artifacts present | PASS | CKO, KP, EP and QA are present. |
| Versioning | PASS | Semantic version 1.0.0 used consistently. |
| File naming | PASS | PP number, full title, GOLD and version included in package name. |
| Boundary declaration | PASS | One clean final-response Boundary is used. |
| Boundary ownership | PASS | Core/Supporting/Excluded/Delegated structure is preserved. |
| Knowledge Graph | PASS | Required graph relationships are defined. |
| Evidence traceability | PASS | High-impact claims are mapped to project sources. |
| QA depth | PASS | QA includes all required layers and specialized audits. |
| No next-PP inference | PASS | Package production stops after QA. |

---

# Clinical Safety Review

## Safety Principle 1 — No individualized schedule

The package contains guideline-defined intervals only as contextual descriptions of specific GAST-7 pathways.

It does not tell an individual patient:

> “You should have this test on this date.”

**Result: PASS**

---

## Safety Principle 2 — No false reassurance

The package explicitly states that:

- normal surveillance does not guarantee permanent absence of recurrence;
- five years does not make recurrence biologically impossible.

**Result: PASS**

---

## Safety Principle 3 — No automatic recurrence diagnosis

The package distinguishes:

**abnormal surveillance finding**

from:

**established recurrence**.

**Result: PASS**

---

## Safety Principle 4 — No treatment prescription

The package does not prescribe:

- surgery;
- chemotherapy;
- immunotherapy;
- targeted therapy;
- recurrent-disease treatment.

**Result: PASS**

---

## Safety Principle 5 — Evidence uncertainty preserved

The package explicitly retains NCCN's statement that surveillance strategies after curative-intent R0 resection remain controversial and that prospective evidence is sparse.

**Result: PASS**

---

# Patient Misconception Review

| Misconception | Addressed? |
|---|---|
| Treatment finished = no follow-up | PASS |
| Surveillance = cancer still present | PASS |
| Everyone has same schedule | PASS |
| Surveillance = CT only | PASS |
| Abnormal test = recurrence | PASS |
| Normal scan = guaranteed cure | PASS |
| Five years = no more healthcare | PASS |
| More testing = always better | PASS |
| Endoscopy always required after gastrectomy | PASS |
| Surveillance only looks for recurrence | PASS |

**Patient Misconception Review: PASS**

---

# Adjacent PP Overlap Audit

## PP-0219 — Post-treatment Imaging

**Risk:** Imaging duplication.

**Resolution:** PP-0219 owns imaging as a post-treatment reassessment event; PP-0220 owns longitudinal surveillance and uses imaging only as a surveillance component.

**Result: PASS**

---

## PP-0221 — Recurrence Detection

**Risk:** Surveillance could expand into recurrence diagnosis.

**Resolution:** PP-0220 stops at identifying concerning findings and routing to further evaluation.

**Result: PASS**

---

## PP-0222 — Management of Recurrent Gastric Cancer

**Risk:** Surveillance could begin describing recurrent treatment.

**Resolution:** No recurrent-treatment algorithm is included.

**Result: PASS**

---

## PP-0229 — Gastric Cancer Survivorship

**Risk:** Nutritional and long-term care could duplicate survivorship.

**Resolution:** PP-0220 owns nutritional monitoring as a surveillance interface; detailed survivorship management is delegated.

**Result: PASS**

---

## PP-0230 — Long-term Follow-up

**Risk:** Five-year follow-up could duplicate long-term follow-up.

**Resolution:** PP-0220 owns the principal cancer-specific surveillance framework; PP-0230 owns broader long-term continuity.

**Result: PASS**

---

# Evidence Traceability Audit

## High-priority traceable claims

| Claim Domain | Traceability | Result |
|---|---|---|
| GAST-7 architecture | NCCN v2.2026 | PASS |
| GAST-H principles | NCCN v2.2026 | PASS |
| H&P timing | NCCN GAST-7 | PASS |
| CBC/chemistry | NCCN GAST-7 | PASS |
| EGD timing | NCCN GAST-7 | PASS |
| CT timing | NCCN GAST-7 | PASS |
| Total gastrectomy endoscopy | NCCN GAST-7 | PASS |
| Nutritional deficiencies | NCCN GAST-7/GAST-I | PASS |
| Recurrence timing | NCCN GAST-H | PASS |
| Late relapse | NCCN GAST-H | PASS |
| Evidence uncertainty | NCCN GAST-H | PASS |
| Survivorship interface | NCCN GAST-I | PASS |

**Evidence Traceability Audit: PASS**

---

# Numerical Evidence Audit

Numerical claims were explicitly checked.

| Numerical claim | Status |
|---|---|
| H&P every 3–6 months for 1–2 years | PASS |
| H&P every 6–12 months for 3–5 years | PASS |
| EGD every 6 months for 1 year after ER | PASS |
| EGD annually thereafter in specified ER pathways | PASS |
| CT every 6 months for first 2 years in specified pStage II/III or ypStage I–III pathway | PASS |
| CT annually up to 5 years in that pathway | PASS |
| 70–80% recurrence within 2 years | PASS |
| ~90% recurrence by 5 years | PASS |

No unsupported numerical thresholds were introduced.

**Numerical Evidence Audit: PASS**

---

# Knowledge Graph Audit

| Relationship | Result |
|---|---|
| Prerequisite PPs | PASS |
| Related PPs | PASS |
| Downstream recurrence | PASS |
| Downstream recurrent management | PASS |
| Survivorship transition | PASS |
| Long-term follow-up transition | PASS |
| Imaging delegation | PASS |
| Endoscopy delegation | PASS |
| Nutrition delegation | PASS |
| Toxicity delegation | PASS |

**Knowledge Graph Audit: PASS**

---

# Gold Depth Integrity Review

## Rule

Gold depth is a minimum standard relative to the approved Gold references.

The package must not be:

- compacted;
- shortened;
- summarized;
- structurally reduced;
- evidence-thinned;
- QA-thinned;
- Knowledge-Graph-thinned;
- patient-facing-depth-thinned.

## Review

### 01_CKO

Contains:

- full metadata;
- objectives;
- primary educational question;
- scope;
- independent clinical knowledge blocks;
- patient explanation;
- clinical importance;
- key concepts;
- evidence maturity;
- misconceptions;
- patient questions;
- key messages;
- safety boundary;
- Knowledge Graph;
- revision history.

**PASS**

### 02_KNOWLEDGE_PASSPORT

Contains:

- identity;
- classification;
- patient journey;
- runtime usage;
- retrieval tags;
- knowledge units;
- evidence maturity;
- authoritative sources;
- governance;
- Knowledge Graph;
- boundary map;
- safety/runtime rules;
- traceability;
- versioning.

**PASS**

### 03_PRIMARY_EVIDENCE_PACKAGE

Contains:

- clinical question;
- educational intent;
- scope;
- primary/supporting sources;
- hierarchy;
- detailed evidence matrix;
- evidence appraisal;
- clinical claims;
- consistency review;
- limitations;
- gaps;
- update triggers;
- patient translation;
- source traceability;
- boundary verification;
- Knowledge Graph;
- final status.

**PASS**

### 04_QA_REPORT

Contains:

- four QA layers;
- clinical safety;
- misconception review;
- overlap audit;
- traceability audit;
- numerical audit;
- Knowledge Graph audit;
- Gold depth audit;
- Source-First audit;
- locked-decision audit;
- cross-artifact consistency;
- package integrity.

**PASS**

### Overall Gold Depth Integrity

**PASS**

---

# Source-First Audit

## Required behavior

The requested PP-specific materials were searched first.

## PP-specific evidence identified

- PP-0220 identity in PP Registry.
- NCCN v2.2026 GAST-7.
- NCCN v2.2026 GAST-H.
- NCCN v2.2026 GAST-I interface.
- NCI treatment context.
- NCI special-population post-gastrectomy context.
- ESMO-ASCO supporting framework.
- ACS patient-facing context.

## Result

**PASS — source-first evidence basis established before artifact production.**

---

# Locked Decision Integrity

The artifacts preserve the approved PP-0220 Decision Batch decisions:

1. Longitudinal surveillance is the core ownership.
2. Surveillance is distinct from post-treatment imaging.
3. Surveillance is distinct from recurrence detection.
4. Surveillance is distinct from survivorship.
5. Stage/treatment dependence is core.
6. ER-specific surveillance is included.
7. Surgical surveillance is included.
8. Total-gastrectomy distinction is included.
9. Nutritional monitoring is included.
10. Imaging is included only at surveillance-level ownership.
11. Routine tumor-marker scheduling is not invented.
12. Evidence uncertainty is explicitly retained.
13. Five-year surveillance is not presented as a biological guarantee.
14. Downstream recurrence and survivorship boundaries are preserved.

**Result: PASS**

---

# Cross-artifact Consistency

| Topic | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| Primary question | ✓ | ✓ | ✓ | ✓ | PASS |
| Scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Stage/treatment dependence | ✓ | ✓ | ✓ | ✓ | PASS |
| EGD | ✓ | ✓ | ✓ | ✓ | PASS |
| Imaging | ✓ | ✓ | ✓ | ✓ | PASS |
| Nutritional monitoring | ✓ | ✓ | ✓ | ✓ | PASS |
| Five-year framework | ✓ | ✓ | ✓ | ✓ | PASS |
| Recurrence boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Survivorship boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Safety rules | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |

**Cross-artifact consistency: PASS**

---

# Package Integrity

Expected package:

```text
PP-0220_Surveillance_After_Gastric_Cancer_Treatment_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

All four artifacts are present.

No extra clinical artifact was introduced.

No required artifact is missing.

**Package Integrity: PASS**

---

# Final QA Decision

## Content QA

**PASS**

## Clinical QA

**PASS**

## Educational QA

**PASS**

## Governance QA

**PASS**

## Clinical Safety Review

**PASS**

## Patient Misconception Review

**PASS**

## Adjacent PP Overlap Audit

**PASS**

## Evidence Traceability Audit

**PASS**

## Numerical Evidence Audit

**PASS**

## Knowledge Graph Audit

**PASS**

## Gold Depth Integrity Review

**PASS**

## Source-First Audit

**PASS**

## Locked Decision Integrity

**PASS**

## Cross-artifact Consistency

**PASS**

## Package Integrity

**PASS**

---

# Final QA Status

**PASS — GOLD — READY FOR INTEGRATION**

---

# Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA following approved and locked PP-0220 Decision Batch. |
